Basket | Login

 
 
 
 

Science watch

 

Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

21/01/2021 Recent Think Brain Health conference focused on personalised plans, blood biomarkers and early conversations
20/01/2021 Trials@Home consortium invites patients and patient organisations to complete a survey on Remote Decentralised Clinical Trials
12/01/2021 LSP and Philip Scheltens launch new, unique fund to fight dementia
11/01/2021 Biogen launches new virtual research study with Apple, aiming to develop digital biomarkers to monitor cognitive performance and decline
11/01/2021 Eli Lilly announces positive top results from Phase II study of donanemab in Alzheimer’s disease
05/01/2021 BioXcel Therapeutics announces positive results from its TRANQUILITY study for the treatment of agitation in dementia
31/12/2020 Axsome Therapeutics launches a Phase III trial of AXS-05 in AD agitation
23/12/2020 European Academy of Neurology/European Alzheimer’s Disease Consortium publishes position paper on diagnostic disclosure, biomarker counselling, and management of patients with mild cognitive impairment
21/12/2020 Invitation to European Researchers to join forthcoming European Crucible which will gather European future research leaders with their counterparts from Scottish institutions
16/12/2020 AB Science announces positive results from Phase II/III of Masitinib in Alzheimer’s disease
16/12/2020 Evaluating the Alzheimer’s disease data landscape: issues with heterogeneity, bias and interoperability
16/12/2020 Novo Nordisk plans to initiate Phase III trial of semaglutide in early AD
15/12/2020 TouchNEUROLOGY discusses emerging therapeutic targets for Alzheimer’s disease with Bengt Winblad
15/12/2020 Clinical study emphasises the importance of good heart health in midlife for dementia prevention in later years
15/12/2020 vTv Therapeutics’s experimental AD drug fails to meet its primary endpoint in Phase II study

 

 

Options